72 related articles for article (PubMed ID: 8956232)
1. Antisense and the kidney.
Oberbauer R; Murer H; Schreiner GF; Meyer TW
Kidney Blood Press Res; 1996; 19(5):221-4. PubMed ID: 8956232
[TBL] [Abstract][Full Text] [Related]
2. The activity of c-myb antisense oligonucleotide to prevent intimal hyperplasia is nonspecific.
Castier Y; Chemla E; Nierat J; Heudes D; Vasseur MA; Rajnoch C; Bruneval P; Carpentier A; Fabiani JN
J Cardiovasc Surg (Torino); 1998 Feb; 39(1):1-7. PubMed ID: 9537527
[TBL] [Abstract][Full Text] [Related]
3. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
[TBL] [Abstract][Full Text] [Related]
4. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
[TBL] [Abstract][Full Text] [Related]
5. Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma.
Mateo-Lozano S; Gokhale PC; Soldatenkov VA; Dritschilo A; Tirado OM; Notario V
Clin Cancer Res; 2006 Nov; 12(22):6781-90. PubMed ID: 17121899
[TBL] [Abstract][Full Text] [Related]
6. Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine.
Oberbauer R
Wien Klin Wochenschr; 1997 Jan; 109(2):40-6. PubMed ID: 9123943
[TBL] [Abstract][Full Text] [Related]
7. Central administration of small interfering RNAs in rats: a comparison with antisense oligonucleotides.
Senn C; Hangartner C; Moes S; Guerini D; Hofbauer KG
Eur J Pharmacol; 2005 Oct; 522(1-3):30-7. PubMed ID: 16213482
[TBL] [Abstract][Full Text] [Related]
8. Antisense oligonucleotides as therapeutics for malignant diseases.
Ho PT; Parkinson DR
Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
[TBL] [Abstract][Full Text] [Related]
9. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
Thomas SM; Ogagan MJ; Freilino ML; Strychor S; Walsh DR; Gooding WE; Grandis JR; Zamboni WC
Mol Pharmacol; 2008 Mar; 73(3):627-38. PubMed ID: 18025070
[TBL] [Abstract][Full Text] [Related]
10. Antisense strategies to inhibit restenosis.
Lee M; Simon AD; Stein CA; Rabbani LE
Antisense Nucleic Acid Drug Dev; 1999 Oct; 9(5):487-92. PubMed ID: 10555157
[TBL] [Abstract][Full Text] [Related]
11. RAF antisense oligonucleotide as a tumor radiosensitizer.
Kasid U; Dritschilo A
Oncogene; 2003 Sep; 22(37):5876-84. PubMed ID: 12947394
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides.
Bennett MR; Anglin S; McEwan JR; Jagoe R; Newby AC; Evan GI
J Clin Invest; 1994 Feb; 93(2):820-8. PubMed ID: 8113414
[TBL] [Abstract][Full Text] [Related]
13. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo.
Simons M; Edelman ER; DeKeyser JL; Langer R; Rosenberg RD
Nature; 1992 Sep; 359(6390):67-70. PubMed ID: 1522889
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the androgen receptor by antisense oligonucleotides regulates the biological activity of androgens in SZ95 sebocytes.
Fimmel S; Saborowski A; Térouanne B; Sultan C; Zouboulis CC
Horm Metab Res; 2007 Feb; 39(2):149-56. PubMed ID: 17326011
[TBL] [Abstract][Full Text] [Related]
15. Neuroblastoma targeting by c-myb-selective antisense oligonucleotides entrapped in anti-GD2 immunoliposome: immune cell-mediated anti-tumor activities.
Brignole C; Marimpietri D; Pagnan G; Di Paolo D; Zancolli M; Pistoia V; Ponzoni M; Pastorino F
Cancer Lett; 2005 Oct; 228(1-2):181-6. PubMed ID: 15936140
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer.
Watson PH; Pon RT; Shiu RP
Cancer Res; 1991 Aug; 51(15):3996-4000. PubMed ID: 1855215
[TBL] [Abstract][Full Text] [Related]
17. Silencing of human c-myc oncogene expression by poly-DNP-RNA.
Shen L; Zhang C; Ambrus JL; Wang JH
Oligonucleotides; 2005; 15(1):23-35. PubMed ID: 15788898
[TBL] [Abstract][Full Text] [Related]
18. A combination treatment of c-myc antisense DNA with all-trans-retinoic acid inhibits cell proliferation by downregulating c-myc expression in small cell lung cancer.
Akie K; Dosaka-Akita H; Murakami A; Kawakami Y
Antisense Nucleic Acid Drug Dev; 2000 Aug; 10(4):243-9. PubMed ID: 10984118
[TBL] [Abstract][Full Text] [Related]
19. Therapy with antisense TGF-beta1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice.
Han DC; Hoffman BB; Hong SW; Guo J; Ziyadeh FN
Am J Physiol Renal Physiol; 2000 Apr; 278(4):F628-34. PubMed ID: 10751224
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of antisense oligonucleotides.
Agrawal S; Temsamani J; Galbraith W; Tang J
Clin Pharmacokinet; 1995 Jan; 28(1):7-16. PubMed ID: 7712663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
